Literature DB >> 33109322

Hereditary angioedema: On-demand treatment of angioedema attacks.

Sandra C Christiansen1, Bruce L Zuraw1.   

Abstract

The availability of effective acute treatment for angioedema has been fundamental in reducing the burden of illness for patients with hereditary angioedema (HAE). In building on the foundation of scientific advances that elucidate the pathomechanism(s) of attacks related to vascular permeability, novel targeted on-demand treatments have been developed and approved. These therapies have provided the means to arrest episodes of swelling, which, in the past, had the potential to inexorably lead to morbidity, and even mortality, for patients with HAE. Access to these medications, along with an emphasis on early administration and guidance that all attacks are candidates for treatment, has shifted the management paradigm for HAE. Although unmet needs remain, these acute therapies, coupled with advances in prophylactic treatment, have furthered the goal for all patients with HAE to live a normal life.

Entities:  

Year:  2020        PMID: 33109322     DOI: 10.2500/aap.2020.41.200066

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  4 in total

1.  Hereditary angioedema again revisited.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2021-03-01       Impact factor: 2.587

2.  Evaluation and management of adverse reactions to the COVID-2019 vaccines.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2022-01-01       Impact factor: 2.587

3.  Long-COVID and loss of smell: A post-COVID olfactory dysfunction that continues to challenge the allergist/immunologist.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2022-03-01       Impact factor: 2.587

4.  Individual approach to long-term therapy in patients with hereditary angioedema (HAE-C1-INH): A case series.

Authors:  S Andarawewa; E Aygören-Pürsün
Journal:  Front Allergy       Date:  2022-08-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.